Centessa Pharmaceuticals (NASDAQ:CNTA) Cut to Hold at Wolfe Research

Wolfe Research lowered shares of Centessa Pharmaceuticals (NASDAQ:CNTA) from an outperform rating to a hold rating in a research note published on Tuesday, MarketBeat reports.

Several other research firms have also commented on CNTA. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Oppenheimer raised their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Finally, Truist Financial raised their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.00.

Centessa Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ CNTA opened at $39.69 on Tuesday. The company’s 50-day simple moving average is $26.93 and its 200-day simple moving average is $25.45. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $40.26. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of -21.69 and a beta of 1.25. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, April 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Equities analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 349,073 shares of company stock valued at $9,429,412 in the last ninety days. 7.09% of the stock is currently owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC increased its stake in shares of Centessa Pharmaceuticals by 34.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after acquiring an additional 3,747,475 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Centessa Pharmaceuticals by 12.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after acquiring an additional 1,246,741 shares during the last quarter. Farallon Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 24.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock valued at $134,480,000 after purchasing an additional 1,045,750 shares during the period. Siren L.L.C. grew its holdings in shares of Centessa Pharmaceuticals by 24.8% in the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock valued at $100,728,000 after purchasing an additional 800,000 shares during the period. Finally, Commodore Capital LP increased its position in Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after purchasing an additional 930,711 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly acquisition reported — Multiple outlets report Eli Lilly will acquire Centessa in a deal worth up to $7.8B; press coverage notes shareholders would receive roughly $38 in cash plus contingent value rights tied to potential upside, which sets a clear takeover premium/floor under the stock. LLY to Buy Centessa — Zacks
• Positive Sentiment: Large call buying — Reports show unusually high volume of call-option purchases, a bullish signal from derivatives traders that may reflect takeover-related arbitrage or speculative upside interest. Investors Purchase Calls — American Banking News
• Neutral Sentiment: Guggenheim reaffirmed “neutral” — Guggenheim left its rating unchanged, signaling no strong analyst upgrade in response to the takeover buzz. Guggenheim Reaffirms — TickerReport
• Neutral Sentiment: Leerink moved to “hold” but raised price target to $40 — A mixed note: downgrading the rating but nudging the target slightly above current market levels, reflecting uncertainty about deal dynamics or timing. Leerink Downgrade / PT — Benzinga
• Negative Sentiment: Multiple analyst downgrades — Several firms (B. Riley, Lifesci Capital, Wolfe Research, Needham, Stephens and others) cut ratings to hold from stronger stances, pressuring sentiment despite the takeover reports. Analyst Downgrades — Zacks Wolfe Research — American Banking News Needham — American Banking News
• Negative Sentiment: Shareholder investigations and class-action alerts — Two law firms announced probes into the proposed sale process and price adequacy, creating legal/transaction risk that can weigh on the stock and complicate closing. Monteverde & Associates — PR Newswire KSF Investigation — BusinessWire
• Negative Sentiment: Earnings miss — Centessa reported Q (EPS -$0.48) that missed consensus (~ -$0.38), an operational disappointment that adds near-term pressure independent of M&A news. Earnings Release — MarketBeat
• Negative Sentiment: Heavy put buying — Separately, unusual volume in put options (10,659 puts, a large jump vs. average) shows some participants betting on downside or using puts for hedging around the deal. (No direct link provided in feed.)

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.